Autologous stem cell transplantation improves microcirculation in systemic sclerosis

Background: In systemic sclerosis (SSc) reduced capillary density decreases blood flow and leads to tissue ischaemia and fingertip ulcers. Nail fold videocapillaroscopy (NVC) is a diagnostic and follow-up parameter useful to evaluate the severity, activity and the stage of SSc microvascular damage. Autologous haemopoietic stem cell transplantation (HSCT) is a new treatment for patients with severe diffuse cutaneous systemic sclerosis (dcSSc) refractory to conventional therapies. We aimed to evaluate the improvement of microvasculature after HSCT using NVC. Methods: A total of 16 patients with severe dcSSc with a “late” videocapillaroscopy pattern underwent an immunesuppressive treatment: 6 were treated with HSCT and 10 with monthly pulse cyclophosphamide (CYC) 1 g for 6 months and then orally with 50 mg/day for further 6 months. NVC was performed before and after 3 months from the beginning of each treatment and then repeated every 3 months. Results: In all patients, before HSCT NVC showed large avascular areas and ramified capillaries and vascular architectural disorganisation (“late” pattern). At 3 months after HSCT, the NVC pattern changed from “late” into “active”, showing frequent giant capillaries (>6/mm) and haemorrhages, absence of avascular areas and angiogenesis phenomena; 1 year after HSCT, microvascular abnormalities were still in the “active” pattern. In patients treated with CYC, no NVC modifications were observed during 24 months of follow-up and the pattern always remained “late”. Conclusions: These results indicate that HSCT with a high dose CYC regimen may foster vascular remodelling, while CYC at lower doses and with a chronic regimen does not influence the microvasculature.

[1]  M. Cerinic,et al.  Pulmonary fibrosis in systemic sclerosis: is treatment with cyclophosphamide more effective than placebo? , 2007, Nature Clinical Practice Rheumatology.

[2]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[3]  T. Moore,et al.  Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. , 2006, Rheumatology.

[4]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[5]  K. Sullivan,et al.  Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. , 2006, Arthritis and rheumatism.

[6]  D. Hicklin,et al.  Granulocyte colony‐stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  M. Sykes,et al.  Treatment of severe autoimmune disease by stem-cell transplantation , 2005, Nature.

[8]  Y. Ikeda,et al.  Defective vasculogenesis in systemic sclerosis , 2004, The Lancet.

[9]  F. Breedveld,et al.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry , 2004, Annals of the rheumatic diseases.

[10]  Till Acker,et al.  Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.

[11]  Maurizio Cutolo,et al.  Raynaud's phenomenon and the role of capillaroscopy. , 2003, Arthritis and rheumatism.

[12]  M. Matucci-Cerinic,et al.  Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders , 2003, Expert opinion on biological therapy.

[13]  G. Valentini.  The assessment of the patient with systemic sclerosis. , 2003, Autoimmunity reviews.

[14]  Y. Konttinen,et al.  Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. , 2002, Clinical and experimental rheumatology.

[15]  R. Wise,et al.  Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis , 2000, Annals of Internal Medicine.

[16]  E F Ring,et al.  Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. , 1996, Annals of the rheumatic diseases.

[17]  E. Atra,et al.  Panoramic nailfold capillaroscopy: a new reading method and normal range. , 1990, Seminars in arthritis and rheumatism.

[18]  H. Maricq,et al.  Widefield capillary microscopy. technique and rating scale for abnormalities seen in scleroderma and related disorders , 1981 .

[19]  Kahaleh Mb.  Vascular involvement in systemic sclerosis (SSc). , 2004 .

[20]  A. Silman,et al.  The assessment of the patient with systemic sclerosis. Introduction. , 2003, Clinical and experimental rheumatology.

[21]  A. Gratwohl,et al.  The use of high dose immunoablative therapy with hematopoietic stem cell support therapy in the treatment of severe autoimmune diseases , 2002, International journal of hematology.

[22]  A Sulli,et al.  Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. , 2000, The Journal of rheumatology.

[23]  J. F. Wolfe,et al.  Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. , 1980, Arthritis and rheumatism.